Should I buy Johnson & Johnson stock in 2025?

What is Johnson & Johnson?

Important information

Note: Johnson & Johnson highlights net income and operating margins; EBITDA not separately disclosed in US GAAP reports.

How much is the Johnson & Johnson stock?

The price of Johnson & Johnson stock is rising this week. As of now, JNJ trades at $153.58, up $1.15 (+0.75%) over the last 24 hours and posting a weekly gain of 0.26%. The company’s market capitalization stands at $369.52 billion, with an average three-month daily volume of 9.39 million shares.

With its low volatility and robust dividend, JNJ remains an appealing choice for Irish investors seeking stability and steady returns.

Our complete analysis of Johnson & Johnson stock

Having thoroughly reviewed Johnson & Johnson’s most recent financial disclosures and dissected its share price trajectory over the past three years, we have employed proprietary algorithms that synthesise a multitude of data points—ranging from quantitative financial ratios to technical momentum signals, sector trends, and benchmarks versus global peers. The resulting picture is robust, as Johnson & Johnson continues to demonstrate resilience and potential across key metrics. So, why might Johnson & Johnson stock once again become a strategic entry point into the global healthcare and medtech sector in 2025?

Recent Performance and Market Context

Johnson & Johnson (NYSE: JNJ) has posted a measured but resilient performance, navigating the turbulence of the broader market with composure. As of 30 May 2025, JNJ stands at $153.58 per share, with a gain of 6.33% over the prior twelve months and 6.20% year-to-date. Notably, the stock’s modest six-month slip of 0.92% reflects sector-wide rotation, not fundamental weakness, and is offset by a strong, upward longer-term trend.

Central to this stability are several positive developments:

• The Q4 2024 earnings release beat consensus, with quarterly sales of $22.52 billion (+5.3% YoY), outpacing estimates and reinforcing management's operational discipline and revenue momentum.
• Johnson & Johnson’s annual results showcased total revenue of $88.82 billion, with adjusted net profit of $14.07 billion, marking reliable growth within a challenging macro environment.
• The dividend yield remains a highlight at 3.39%, sustaining interest amongst income-oriented investors.
• Market consensus is constructive: with a cluster of analyst price targets in the $159–$249 range and zero sell ratings, the professional investment community is signalling confidence in JNJ’s forward trajectory.

From a macro sector perspective, global healthcare remains an outperformer within defensive allocations—bolstered by demographic megatrends, continuous innovation, and heightened demand for quality care. For Irish investors with global portfolios, JNJ offers a unique fusion of dollar exposure and low beta (0.41), mitigating volatility during periods of wider market stress.

Technical Analysis

Technical indicators for JNJ as we move into mid-2025 are sending encouraging signals for a potential bullish rotation:

• Relative Strength Index (RSI 14): Sitting in a neutral band (48–54), JNJ is neither overbought nor oversold, often interpreted as a balanced foundation from which positive surprise moves can launch.
• Moving Average Convergence Divergence (MACD): Although variable, most recent readings between -0.99 and +0.2 suggest convergence towards a positive crossover. This emerging technical balance—especially following consolidation within a multi-month price rectangle—signals a likely move away from support.
• Support and Resistance: The stock has been resilient above its $140.68 52-week low, bouncing twice off this base since late 2024. Immediate resistance at $156.81 and the technical ceiling at $169.99 mark clear reference points. The current share price offers proximity to technical supports ($151–$153), suggesting an attractive risk/reward for new positions.
• Simple Moving Averages: JNJ’s range-bound activity between $141 and $169 through 2024/2025 reflects a healthy consolidation phase, with the potential for an upside break should sectoral tailwinds intensify.

In summary, technical structure is supportive for both short- and medium-term positioning, with downside well-cushioned and upside potential unfolding.

Fundamental Analysis

Johnson & Johnson’s fundamental strengths remain a cornerstone for value-seekers and growth-oriented investors alike:

• Revenue and Profitability: 2024 annual growth was robust—revenues grew 4.3%, and adjusted operational growth reached 7%. Beating consensus estimates in recent quarters bolsters management’s credibility.
• Attractive Valuation: The current P/E (TTM) stands at 17.07, with a forward P/E of just 14.51—appealing relative to both historical levels and peer averages across global pharma and medtech. This appears particularly competitive when set against a rising-rate environment, where earnings quality and predictability command premium multiples.
• Dividend Strength: A dividend yield of 3.39% (with quarterly payouts of $1.30) offers a compelling stream of income in the context of subdued sovereign yields, and the company is a Dividend Aristocrat with a long-standing history of stable or rising annual distributions.
• Strategic Moat: Johnson & Johnson’s leadership in immunology, oncology, and medtech is underpinned by a globally trusted brand, proprietary innovation, and geographical diversification. This structural advantage is the backbone of a company that consistently captures share and sustains margin—qualities that often underpin multi-year compound price appreciation.

Volume and Liquidity

Volume and liquidity indicators further reinforce market confidence and the stock’s flexibility for portfolio construction:

• Average Daily Volume: At 9.39 million shares (3-month average), JNJ is among the most liquid blue-chips globally. This ensures that both institutional and retail investors can build, alter or exit positions with minimal slippage—a crucial attribute for managing risk in volatile markets.
• Float Dynamics: The large free-float, anchored by institutional holders such as Vanguard, SPDR, and Fidelity, contributes to a dynamic yet stable valuation environment. High-quality institutional ownership is often a signal of robust underlying confidence and corporate governance.

Catalysts and Positive Outlook

Multiple near-term and secular catalysts are converging to reinforce JNJ’s upside narrative:

• Innovation Portfolio: 2025 is widely viewed as a “catalyst year” for Johnson & Johnson, with pipeline launches in Innovative Medicine and MedTech segments. The company’s continued investments in immunology, oncology, and neuroscience set the stage for margin expansion and renewed growth.
• Expansion and Partnerships: Geographical diversification and strategic partnerships remain at the forefront, supporting resilient international sales even amid fluctuating currencies and adding optionality in emerging markets.
• Sector Tailwinds: Favourable demographic trends—particularly ageing populations in developed economies—are fuelling demand for chronic care, biopharma advancements, and cutting-edge devices. Johnson & Johnson is strategically positioned to capitalise on these intensifying global health needs.
• ESG and Sustainability: The company’s continued focus on transparency, product safety, and sustainability further buttresses its global appeal, both to institutional asset managers and to individual investors increasingly focused on ESG principles.

Importantly, JNJ’s governance remains robust under Joaquin Duato, and the upcoming earnings report on 16 July 2025 is expected to further clarify the outlook and perhaps catalyse renewed market enthusiasm.

Investment Strategies

Given its unique blend of stability, value, and growth optionality, Johnson & Johnson’s current technical and fundamental setup lends itself to several strategic investment approaches:

• Short-term entry: With the share price hugging a major technical support zone ($151–$153), agile investors may see an opportune trade on a forthcoming technical bounce, especially if the post-earnings momentum in July proves favourable.
• Medium-term positioning: Should JNJ break through initial resistance at $156.81 on robust volume, there is scope for a push towards the consensus price target ($170), offering meaningful appreciation while collecting dividends.
• Long-term accumulation: For those with a horizon spanning years, layering exposure at current valuations allows for compounding dividend reinvestment, supported by Johnson & Johnson’s unrivalled brand, conservative balance sheet, and pipeline-led innovation. The stock’s low beta also makes it a natural counterbalance within diversified, multi-asset portfolios.
• Ideal positioning: New entry points near current levels, well supported by technical structure and approaching the second-quarter results, may provide an advantageous springboard into what appears to be a reinvigorated upward phase.

Is it the Right Time to Buy Johnson & Johnson?

In summary, Johnson & Johnson stands out as a high-calibre investment vehicle: its compelling valuation, robust and growing dividend, industry-leading fundamentals, and exceptionally low volatility set it apart—particularly at a time when defensiveness and quality are highly prized. With multiple growth catalysts on the horizon and ongoing operational outperformance, the stock seems well poised for a bullish phase, and its fundamental profile justifies renewed interest from both income-seekers and growth-focused investors.

While all investments carry elements of risk, Johnson & Johnson’s current setup—undervalued relative to its sector and intrinsic worth, supported by strong technical and liquidity foundations, and with positive momentum in key business segments—suggests that now could represent an excellent opportunity to gain exposure to a core healthcare leader. For Irish investors seeking to add stability, consistent income, and credible growth potential to their portfolios, Johnson & Johnson’s prospects appear particularly attractive as 2025 unfolds.

In a market searching for quality at a reasonable price, the unique strengths and reliable performance of Johnson & Johnson offer an entry point that, from both technical and fundamental perspectives, inspires confidence.

How to buy Johnson & Johnson stock in Ireland?

Buying Johnson & Johnson (JNJ) stock online is both simple and secure, provided you use a regulated broker based in Ireland or the EU. Today’s platforms make it easy for retail investors to purchase JNJ shares in just a few clicks, with your investment protected by strict financial regulations. You can choose to invest using two primary methods: buying shares outright (“spot buying” or cash purchase) or trading Contracts for Difference (CFDs) to speculate on price movements with leverage. To help you select the right platform for your needs, see our detailed broker comparison further down the page.

Spot Buying

A cash purchase means outright ownership of Johnson & Johnson shares—you become a part-owner of the company, entitled to dividends and voting rights. Irish brokers typically charge a fixed commission per trade, often around €5 to €10, sometimes converted to USD for US stocks.

Example

Suppose the Johnson & Johnson share price is $153.58 (as of 30 May 2025). With a stake of $1,000, after including a typical brokerage fee of $5, you can buy approximately 6.47 shares ($1,000 - $5 = $995 / $153.58 ≈ 6.47).

Gain scenario

If the share price rises by 10% to $168.94, your shares are now worth about $1,100.
Result: +$100 gross gain, i.e., +10% on your investment (excluding any currency conversion costs).

Trading via CFD

CFD trading allows you to speculate on the price movement of Johnson & Johnson shares without owning the stock itself. With CFDs, you can use leverage—invest a small amount to control a larger position. The broker charges a “spread” (the difference between buy and sell price), and if you hold positions overnight, a financing cost applies.

Example

For example, with a stake of $1,000 and 5x leverage, you can open a CFD position representing $5,000 of market exposure on JNJ shares.

Gain scenario

If the stock rises by 8%, your leveraged position earns 8% × 5 = 40%.
Result: That’s a gain of $400 on your $1,000 margin (excluding spread and overnight fees).

Final Advice

It’s essential to compare broker fees, currency conversion costs, and trading conditions before you invest—these can vary significantly and impact your returns. Whether you wish to build long-term wealth through ownership (“spot buying”) or seek short-term opportunities with leverage (CFDs), the choice ultimately depends on your financial goals and risk profile. For a detailed comparison of leading brokers in Ireland, explore the comparator further down the page. Always invest with care and choose the approach that best fits your personal strategy.

Our 7 tips for buying Johnson & Johnson stock

The latest news about Johnson & Johnson

Johnson & Johnson reported positive weekly stock performance and declared a robust quarterly dividend for May 2025. The company’s share price as of 30 May 2025 stood at $153.58, marking a weekly gain of +0.26% and an intraday increase of +0.75%, reflecting underlying investor confidence. The ex-dividend date of 27 May 2025 confirmed a stable, attractive quarterly dividend of $1.30 per share, yielding 3.39%. These defensive characteristics—very low five-year beta (0.41), consistent dividend policy, and resilient pricing—underscore JNJ’s appeal to risk-averse investors, including those in Ireland who value steady income and capital preservation in healthcare allocations.

Analyst consensus remains robustly positive, with upward price targets and no sell recommendations over the past week. The average analyst price objective for JNJ ranges from $170.09 to $170.84, indicating a potential upside of approximately 10-11% from current levels, with upper targets cited as high as $248.64. Importantly, the latest consensus registers 23 buy recommendations, 22 holds, and zero sells, highlighting strong institutional and professional analyst conviction. Such consensus is particularly relevant for Irish investment managers seeking US healthcare exposure: the sector’s stability and positive outlook are aligned with diversified portfolio strategies favored in Ireland.

Johnson & Johnson’s financials continue to outperform, with annual and quarterly growth exceeding market expectations. Annual revenue for 2024 reached $88.82 billion, up 4.3% year-on-year, with net profit at $14.07 billion and operational growth of 7%. The most recent quarter (Q4 2024) saw sales rise to $22.52 billion, outperforming analyst expectations and registering a 6.7% operational gain. The company’s consistently strong results offer upside for Irish institutional investors and pension funds, which frequently seek resilient, blue-chip multinationals to fulfill long-term obligations.

Innovation in pharma and medtech continues to drive portfolio expansion and geographic reach, with positive implications for the Irish market. Johnson & Johnson is highlighted as a 2025 “catalyst year,” driven by developments in Innovative Medicine and MedTech segments where JNJ has a global leadership presence—including in Ireland. The company has established significant operations in Ireland—across research, manufacturing, and distribution—benefiting from an ecosystem of local partnerships and a favorable regulatory environment. This strengthens both employment and supply chains, making JNJ’s stability and innovation highly relevant for Ireland-based stakeholders.

Forthcoming Q2 2025 results and ongoing dividend stability position Johnson & Johnson favorably ahead of key mid-year disclosures. With the next earnings release set for 16 July 2025, the market’s positive momentum and stable financials are expected to persist, further supported by a solid dividend history. Irish investors, including those in pension and insurance sectors, are closely monitoring these developments as JNJ’s shares remain a cornerstone for euro-USD diversification strategies and healthcare sector exposure within regulated Irish frameworks.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.